These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1001 related articles for article (PubMed ID: 17909199)
1. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. Herbst RS; O'Neill VJ; Fehrenbacher L; Belani CP; Bonomi PD; Hart L; Melnyk O; Ramies D; Lin M; Sandler A J Clin Oncol; 2007 Oct; 25(30):4743-50. PubMed ID: 17909199 [TBL] [Abstract][Full Text] [Related]
2. Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatment rationale and protocol dynamics of the AvaALL (MO22097) trial. Gridelli C; Bennouna J; de Castro J; Dingemans AM; Griesinger F; Grossi F; Rossi A; Thatcher N; Wong EK; Langer C Clin Lung Cancer; 2011 Nov; 12(6):407-11. PubMed ID: 21705281 [TBL] [Abstract][Full Text] [Related]
3. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. Herbst RS; Johnson DH; Mininberg E; Carbone DP; Henderson T; Kim ES; Blumenschein G; Lee JJ; Liu DD; Truong MT; Hong WK; Tran H; Tsao A; Xie D; Ramies DA; Mass R; Seshagiri S; Eberhard DA; Kelley SK; Sandler A J Clin Oncol; 2005 Apr; 23(11):2544-55. PubMed ID: 15753462 [TBL] [Abstract][Full Text] [Related]
4. A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancer. Ciuleanu T; Tsai CM; Tsao CJ; Milanowski J; Amoroso D; Heo DS; Groen HJ; Szczesna A; Chung CY; Chao TY; Middleton G; Zeaiter A; Klingelschmitt G; Klughammer B; Thatcher N Lung Cancer; 2013 Nov; 82(2):276-81. PubMed ID: 23992877 [TBL] [Abstract][Full Text] [Related]
5. Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial. Kim ES; Neubauer M; Cohn A; Schwartzberg L; Garbo L; Caton J; Robert F; Reynolds C; Katz T; Chittoor S; Simms L; Saxman S Lancet Oncol; 2013 Dec; 14(13):1326-36. PubMed ID: 24231627 [TBL] [Abstract][Full Text] [Related]
6. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer. Spigel DR; Burris HA; Greco FA; Shipley DL; Friedman EK; Waterhouse DM; Whorf RC; Mitchell RB; Daniel DB; Zangmeister J; Bass JD; Hainsworth JD J Clin Oncol; 2011 Jun; 29(18):2582-9. PubMed ID: 21576636 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Ciuleanu T; Stelmakh L; Cicenas S; Miliauskas S; Grigorescu AC; Hillenbach C; Johannsdottir HK; Klughammer B; Gonzalez EE Lancet Oncol; 2012 Mar; 13(3):300-8. PubMed ID: 22277837 [TBL] [Abstract][Full Text] [Related]
8. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Seto T; Kato T; Nishio M; Goto K; Atagi S; Hosomi Y; Yamamoto N; Hida T; Maemondo M; Nakagawa K; Nagase S; Okamoto I; Yamanaka T; Tajima K; Harada R; Fukuoka M; Yamamoto N Lancet Oncol; 2014 Oct; 15(11):1236-44. PubMed ID: 25175099 [TBL] [Abstract][Full Text] [Related]
9. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. Socinski MA; Langer CJ; Huang JE; Kolb MM; Compton P; Wang L; Akerley W J Clin Oncol; 2009 Nov; 27(31):5255-61. PubMed ID: 19738122 [TBL] [Abstract][Full Text] [Related]
10. ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer. Johnson BE; Kabbinavar F; Fehrenbacher L; Hainsworth J; Kasubhai S; Kressel B; Lin CY; Marsland T; Patel T; Polikoff J; Rubin M; White L; Yang JC; Bowden C; Miller V J Clin Oncol; 2013 Nov; 31(31):3926-34. PubMed ID: 24101054 [TBL] [Abstract][Full Text] [Related]
11. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. Patel JD; Hensing TA; Rademaker A; Hart EM; Blum MG; Milton DT; Bonomi PD J Clin Oncol; 2009 Jul; 27(20):3284-9. PubMed ID: 19433684 [TBL] [Abstract][Full Text] [Related]
12. Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathways. Sandler A; Herbst R Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4421s-4425s. PubMed ID: 16857821 [TBL] [Abstract][Full Text] [Related]
13. Phase II study of pemetrexed plus intermittent erlotinib combination therapy for pretreated advanced non-squamous non-small cell lung cancer with documentation of epidermal growth factor receptor mutation status. Minami S; Kijima T; Hamaguchi M; Nakatani T; Koba T; Takahashi R; Takeuchi Y; Kida H; Nagatomo I; Yamamoto S; Tachibana I; Komuta K; Kawase I Lung Cancer; 2013 Nov; 82(2):271-5. PubMed ID: 23993733 [TBL] [Abstract][Full Text] [Related]
14. An open-label, multicenter, randomized, phase II study of pazopanib in combination with pemetrexed in first-line treatment of patients with advanced-stage non-small-cell lung cancer. Scagliotti GV; Felip E; Besse B; von Pawel J; Mellemgaard A; Reck M; Bosquee L; Chouaid C; Lianes-Barragán P; Paul EM; Ruiz-Soto R; Sigal E; Ottesen LH; Lechevalier T J Thorac Oncol; 2013 Dec; 8(12):1529-37. PubMed ID: 24389434 [TBL] [Abstract][Full Text] [Related]
15. Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial. Cohen EE; Subramanian J; Gao F; Szeto L; Kozloff M; Faoro L; Karrison T; Salgia R; Govindan R; Vokes EE Clin Lung Cancer; 2012 Mar; 13(2):123-8. PubMed ID: 22100149 [TBL] [Abstract][Full Text] [Related]
16. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. Smit EF; Burgers SA; Biesma B; Smit HJ; Eppinga P; Dingemans AM; Joerger M; Schellens JH; Vincent A; van Zandwijk N; Groen HJ J Clin Oncol; 2009 Apr; 27(12):2038-45. PubMed ID: 19307503 [TBL] [Abstract][Full Text] [Related]
17. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). Barlesi F; Scherpereel A; Rittmeyer A; Pazzola A; Ferrer Tur N; Kim JH; Ahn MJ; Aerts JG; Gorbunova V; Vikström A; Wong EK; Perez-Moreno P; Mitchell L; Groen HJ J Clin Oncol; 2013 Aug; 31(24):3004-11. PubMed ID: 23835708 [TBL] [Abstract][Full Text] [Related]
18. Carboplatin/pemetrexed/bevacizumab in the treatment of patients with advanced non-small-cell lung cancer: a single-institution experience. Malhotra B; Evans T; Weiss J; Eaby B; Stonehouse-Lee S; Sherry V; Langer CJ Clin Lung Cancer; 2010 May; 11(3):192-7. PubMed ID: 20439196 [TBL] [Abstract][Full Text] [Related]
19. A randomised phase II study of pemetrexed versus pemetrexed+erlotinib as second-line treatment for locally advanced or metastatic non-squamous non-small cell lung cancer. Dittrich C; Papai-Szekely Z; Vinolas N; Sederholm C; Hartmann JT; Behringer D; Kazeem G; Desaiah D; Leschinger MI; von Pawel J Eur J Cancer; 2014 Jun; 50(9):1571-80. PubMed ID: 24703574 [TBL] [Abstract][Full Text] [Related]
20. Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with non-squamous non-small cell lung cancer. Lee DH; Lee JS; Kim SW; Rodrigues-Pereira J; Han B; Song XQ; Wang J; Kim HK; Sahoo TP; Digumarti R; Wang X; Altug S; Orlando M Eur J Cancer; 2013 Oct; 49(15):3111-21. PubMed ID: 23890768 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]